Aligos Therapeutics, Inc.
ALGS
$5.60
-$0.16-2.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 90.52% | -153.47% | 75.80% | -63.75% | -413.44% |
| Total Depreciation and Amortization | -1.54% | 78.35% | 6.64% | -11.29% | 1.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -45.90% | 96.70% | -99.54% | 160.04% | 97.13% |
| Change in Net Operating Assets | -2,518.28% | 140.60% | -518.97% | 148.15% | -77.38% |
| Cash from Operations | -60.93% | -10.61% | -18.16% | -21.11% | 20.46% |
| Capital Expenditure | 99.08% | -60.47% | -228.57% | -642.31% | -1,457.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 163.59% | 179.50% | -109.65% | 359.29% | -198.28% |
| Cash from Investing | 163.42% | 179.27% | -110.12% | 358.58% | -198.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1,500.00% | -- | 93.02% | -100.00% | 93.75% |
| Issuance of Common Stock | -- | -- | -10.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 224.29% | -100.06% | 26.80% | -1,225.00% | -162.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.49% | -68.07% | -1,519.15% | 339.88% | -365.16% |